Neurodegenerative disorders management: state-of-art and prospects of nano-biotechnology

References

• GBD. 2016. Data Resources|GHDx n.d. [cited accessed 2020 Oct 7]. Available from: http://ghdx.healthdata.org/gbd-2016
   Google Scholar
• Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol. 2016;15(9):913–924.
   PubMed Web of Science ®Google Scholar
• Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1204–1222.
   PubMed Web of Science ®Google Scholar
• Medicines in Development for Neurological Disorders 2018. Report|PhRMA n.d. [cited 2021 May 24]. Available from: https://www.phrma.org/en/Report/Medicines-in-Development-for-Neurological-Disorders-2018-Report
   Google Scholar
• Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–162.
   PubMed Web of Science ®Google Scholar
• Medicines in Development for Neurological Disorders 2018 Report|PhRMA n.d. [cited 2021 May 20]. Available from: https://www.phrma.org/en/Report/Medicines-in-Development-for-Neurological-Disorders-2018-Report
   Google Scholar
• Medicines in development for neurological disorders a report on disorders of the brain, spinal cord and nerves biopharmaceutical researchers are developing more than 400 medicines for wide range of neurological disorders. n.d.
   Google Scholar
• Medicines in Development for Neurological Disorders 2018 Report|PhRMA n.d. [cited 2020 Oct 7]. Available from: https://www.phrma.org/Report/Medicines-in-Development-for-Neurological-Disorders-2018-Report
   Google Scholar
• Chaudhary U, Birbaumer N, Curado MR. Brain-machine interface (BMI) in paralysis. Ann Phys Rehabil Med. 2015;58(1):9–13.
   PubMed Web of Science ®Google Scholar
• Branco MP, Pels EGM, Sars RH, et al. Brain-Computer interfaces for communication: Preferences of individuals with locked-in syndrome. Neurorehabil Neural Repair. 2021;35(3):267–279.
   PubMed Web of Science ®Google Scholar
• Burns A, Adeli H, Buford JA. Brain-computer interface after nervous system injury. Neuroscientist. 2014;20(6):639–651.
   PubMed Web of Science ®Google Scholar
• Buch E, Weber C, Cohen LG, et al. Think to move: a neuromagnetic brain-computer interface (BCI) system for chronic stroke. Stroke. 2008;39(3):910–917.
   PubMed Web of Science ®Google Scholar
• Birbaumer N, Murguialday AR, Cohen L. Brain-computer interface in paralysis. Curr Opin Neurol. 2008;21(6):634–638.
   PubMed Web of Science ®Google Scholar
• Friehs GM, Zerris VA, Ojakangas CL, et al. Brain-machine and brain-computer interfaces. Stroke. 2004;35:2702–2705.
   PubMed Web of Science ®Google Scholar
• Wolpaw JR, McFarland DJ. Control of a two-dimensional movement signal by a noninvasive brain-computer interface in humans. Proc Natl Acad Sci USA. 2004;101:17849–17854.
   PubMed Web of Science ®Google Scholar
• Chase SM, Schwartz AB, Kass RE. Bias, optimal linear estimation, and the differences between open-loop simulation and closed-loop performance of spiking-based brain-computer interface algorithms. Neural Netw. 2009;22(9):1203–1213.
   PubMed Web of Science ®Google Scholar
• Allison BZ, Wolpaw EW, Wolpaw JR. Brain-computer interface systems: progress and prospects. Expert Rev Med Devices. 2007;4(4):463–474.
   PubMed Web of Science ®Google Scholar
• Ramadan RA, Vasilakos AV. Brain computer interface: control signals review. Neurocomputing. 2017;223:26–44.
   Web of Science ®Google Scholar
• Tiwari N, Edla DR, Dodia S, et al. Brain computer interface: a comprehensive survey. Biol Inspired Cognit Archit. 2018;26:118–129.
   Google Scholar
• Ramadan RA, Refat S, Elshahed MA, et al. Basics of brain computer interface. Intell Syst Ref Libr. 2015;74:31–50.
   Google Scholar
• Hochberg LR, Serruya MD, Friehs GM, et al. Neuronal ensemble control of prosthetic devices by a human with tetraplegia. Nature. 2006;442(7099):164–171.
   PubMed Web of Science ®Google Scholar
• Saha S, Mamun KA, Ahmed K, et al. Progress in brain computer interface: challenges and opportunities. Front Syst Neurosci. 2021;15:578875.
   PubMed Web of Science ®Google Scholar
• Blau A. Cell adhesion promotion strategies for signal transduction enhancement in microelectrode array in vitro electrophysiology: an introductory overview and critical discussion. Curr Opin Colloid Interface Sci. 2013;18(5):481–492.
   Web of Science ®Google Scholar
• Konrad P, Shanks T. Implantable brain computer interface: challenges to neurotechnology translation. Neurobiol Dis. 2010;38(3):369–375.
   PubMed Web of Science ®Google Scholar
• Grimaldi G, Manto M. Neurological tremor: sensors, signal processing and emerging applications. Sensors. 2010;10(2):1399–1422.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhao J, Dong Y, et al. Dry electrodes for human bioelectrical signal monitoring. Sensors. 2020;20(13):3630–3651.
   Web of Science ®Google Scholar
• Eckhorn R, Thomas U. A new method for the insertion of multiple microprobes into neural and muscular tissue, including fiber electrodes, fine wires, needles and microsensors. J Neurosci Methods. 1993;49(3):175–179.
   PubMed Web of Science ®Google Scholar
• Vansteensel MJ, Pels EGM, Bleichner MG, et al. Fully implanted brain–computer interface in a Locked-In patient with ALS. N Engl J Med. 2016;375(21):2060–2066.
   PubMed Web of Science ®Google Scholar
• Pels EGM, Aarnoutse EJ, Leinders S, et al. Stability of a chronic implanted brain-computer interface in late-stage amyotrophic lateral sclerosis. Clin Neurophysiol. 2019;130(10):1798–1803.
   PubMed Web of Science ®Google Scholar
• Capogrosso M, Milekovic T, Borton D, et al. A brain-spine interface alleviating gait deficits after spinal cord injury in primates. Nature. 2016;539(7628):284–288.
   PubMed Web of Science ®Google Scholar
• Zamberletti E, Gabaglio M, Woolley-Roberts M, et al. Cannabidivarin treatment ameliorates Autism-Like behaviors and restores hippocampal endocannabinoid system and glia alterations induced by prenatal valproic acid exposure in Rats. Front Cell Neurosci. 2019;13:367.
   PubMed Web of Science ®Google Scholar
• Yoo S-S, Kim H, Filandrianos E, et al. Non-invasive brain-to-brain interface (BBI): establishing functional links between two brains. PLOS One. 2013;8(4):e60410.
   PubMed Web of Science ®Google Scholar
• Grau C, Ginhoux R, Riera A, et al. Conscious brain-to-brain communication in humans using non-invasive technologies. PLOS One. 2014;9(8):e105225.
   PubMed Web of Science ®Google Scholar
• Kitago T, Marshall RS. Strategies for early stroke recovery: what lies ahead? Curr Treat Options Cardio Med. 2015;17(1):356.
   PubMedGoogle Scholar
• Sterr A, Elbert T, Berthold I, et al. Longer versus shorter daily constraint-induced movement therapy of chronic hemiparesis: an exploratory study. Arch Phys Med Rehabil. 2002;83(10):1374–1377.
   PubMed Web of Science ®Google Scholar
• Rocha LSO, Gama GCB, Rocha RSB, et al. Constraint induced movement therapy increases functionality and quality of life after stroke. J Stroke Cerebrovasc Dis. 2021;30(6):105774.
   PubMed Web of Science ®Google Scholar
• Kruskal PB, Jiang Z, Gao T, et al. Beyond the patch clamp: nanotechnologies for intracellular recording. Neuron. 2015;86(1):21–24.
   PubMed Web of Science ®Google Scholar
• Duan X, Fu TM, Liu J, et al. Nanoelectronics-biology frontier: from nanoscopic probes for action potential recording in live cells to three-dimensional cyborg tissues. Nano Today. 2013;8(4):351–373.
   PubMed Web of Science ®Google Scholar
• Bae JR, Kim SH. Synapses in neurodegenerative diseases. BMB Rep. 2017;50(5):237–246.
   PubMed Web of Science ®Google Scholar
• Mazzucchi S, Palermo G, Campese N, et al. The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. Expert Rev Proteomics. 2020;17(7–8):543–559.
   PubMed Web of Science ®Google Scholar
• Lepeta K, Lourenco MV, Schweitzer BC, et al. Synaptopathies: synaptic dysfunction in neurological disorders – a review from students to students. J Neurochem. 2016;138(6):785–805.
   PubMed Web of Science ®Google Scholar
• Jain KK. Role of nanotechnology in developing new therapies for diseases of the nervous system. Nanomedicine. 2006;1(1):9–12.
   PubMed Web of Science ®Google Scholar
• Spira ME, Hai A. Multi-electrode array technologies for neuroscience and cardiology. Nature Nanotech. 2013;8(2):83–94.
   PubMed Web of Science ®Google Scholar
• Mak JN, Wolpaw JR. Clinical applications of brain-computer interfaces: current state and future prospects. IEEE Rev Biomed Eng. 2009;2:187–199.
   PubMedGoogle Scholar
• Sharma A, Rieth L, Tathireddy P, et al. Long term in vitro functional stability and recording longevity of fully integrated wireless neural interfaces based on the Utah slant electrode array. J Neural Eng. 2011;8(4):045004.
   PubMed Web of Science ®Google Scholar
• Angle MR, Cui B, Melosh NA. Nanotechnology and neurophysiology. Curr Opin Neurobiol. 2015;32:132–140.
   PubMed Web of Science ®Google Scholar
• Cobb JLS. Observations on the electrical activity within the retractor muscles of the lantern of Echinus esculentus using extracellular recording electrodes. Comp Biochem Physiol. 1968;24(1):311–316.
   PubMedGoogle Scholar
• Cederquist KB, Kelley SO. Nanostructured biomolecular detectors: pushing performance at the nanoscale. Curr Opin Chem Biol. 2012;16(3–4):415–421.
   PubMed Web of Science ®Google Scholar
• Jacobs J, Kahana MJ. Direct brain recordings fuel advances in cognitive electrophysiology. Trends Cogn Sci. 2010;14(4):162–171.
   PubMed Web of Science ®Google Scholar
• Bagal IV, Johar MA, Hassan MA, et al. Facile morphology control of high aspect ratio patterned Si nanowires by metal-assisted chemical etching. J Mater Sci. 2018;29:18167–18177.
   Web of Science ®Google Scholar
• Dayeh SA, Wang J, Li N, et al. Growth, defect formation, and morphology control of germanium-silicon semiconductor nanowire heterostructures. Nano Lett. 2011;11(10):4200–4206.
   PubMed Web of Science ®Google Scholar
• Chen K-I, Li B-R, Chen Y-T. Silicon nanowire field-effect transistor-based biosensors for biomedical diagnosis and cellular recording investigation. Nano Today. 2011;6(2):131–154.
   Web of Science ®Google Scholar
• Qing Q, Jiang Z, Xu L, et al. Free-standing kinked nanowire transistor probes for targeted intracellular recording in three dimensions. Nat Nanotechnol. 2014;9(2):142–147.
   PubMed Web of Science ®Google Scholar
• Sahasrabuddhe K, Khan AA, Singh AP, et al. The argo: a high channel count recording system for neural recording in vivo. J Neural Eng. 2021;18(1):015002.
   PubMed Web of Science ®Google Scholar
• Rubehn B, Wolff SBE, Tovote P, et al. A polymer-based neural microimplant for optogenetic applications: design and first in vivo study. Lab Chip. 2013;13(4):579–588.
   PubMed Web of Science ®Google Scholar
• Zimmerman JF, Murray GF, Wang Y, et al. Free-standing kinked silicon nanowires for probing inter- and intracellular force dynamics. Nano Lett. 2015;15(8):5492–5498.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kang G, Nam Y, et al. Surface-modified microelectrode array with flake nanostructure for neural recording and stimulation. Nanotechnology. 2010;21:8.
   Web of Science ®Google Scholar
• O'Connell NE, Marston L, Spencer S, et al. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev. 2018;4:CD008208.
   PubMedGoogle Scholar
• Huff W, Lenartz D, Schormann M, et al. Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment-resistant obsessive-compulsive disorder: outcomes after one year. Clin Neurol Neurosurg. 2010;112(2):137–143.
   PubMed Web of Science ®Google Scholar
• Priori A, Foffani G, Rossi L, et al. Adaptive deep brain stimulation (aDBS) controlled by local field potential oscillations. Exp Neurol. 2013;245:77–86.
   PubMed Web of Science ®Google Scholar
• Figee M, Mayberg H. The future of personalized brain stimulation. Nat Med. 2021;27(2):196–197.
   PubMed Web of Science ®Google Scholar
• Benabid AL. Deep brain stimulation for Parkinson's disease. Curr Opin Neurobiol. 2003;13(6):696–706.
   PubMed Web of Science ®Google Scholar
• Gross C, Rougier A, Guehl D, et al. High-frequency stimulation of the globus Pallidus internalis in Parkinson's disease: a study of seven cases. J Neurosurg. 1997;87(4):491–498.
   PubMed Web of Science ®Google Scholar
• Rizzone M, Lanotte M, Bergamasco B, et al. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: effects of variation in stimulation parameters. J Neurol Neurosurg Psychiatry. 2001;71(2):215–219.
   PubMed Web of Science ®Google Scholar
• Neumann WJ, Turner RS, Blankertz B, et al. Toward electrophysiology-based intelligent adaptive deep brain stimulation for movement disorders. Neurotherapeutics. 2019;16(1):105–118.
   PubMed Web of Science ®Google Scholar
• Wichmann T, DeLong MR. Deep brain stimulation for neurologic and neuropsychiatric disorders. Neuron. 2006;52(1):197–204.
   PubMed Web of Science ®Google Scholar
• Chen S, Weitemier AZ, Zeng X, et al. Near-infrared deep brain stimulation via upconversion nanoparticle-mediated optogenetics. Science. 2018;359(6376):679–684.
   PubMed Web of Science ®Google Scholar
• Mazzatenta A, Giugliano M, Campidelli S, et al. Interfacing neurons with carbon nanotubes: electrical signal transfer and synaptic stimulation in cultured brain circuits. J Neurosci. 2007;27(26):6931–6936.
   PubMed Web of Science ®Google Scholar
• Li Y, Li Y, Wang H, et al. Yb3+, Er3+ codoped cerium oxide upconversion nanoparticles enhanced the enzymelike catalytic activity and antioxidative activity for Parkinson's disease treatment. ACS Appl Mater Interfaces. 2021;13(12):13968–13977.
   PubMed Web of Science ®Google Scholar
• Yu N, Huang L, Zhou Y, et al. Near‐infrared‐light activatable nanoparticles for deep‐tissue‐penetrating wireless optogenetics. Adv Healthcare Mater. 2019;8(6):1801132.
   Web of Science ®Google Scholar
• Kumar R, Mondal K, Panda PK, et al. Core–shell nanostructures: perspectives towards drug delivery applications. J Mater Chem B. 2020;8(39):8992–9027.
   Web of Science ®Google Scholar
• Bergfeld IO, Mantione M, Hoogendoorn MLC, et al. Cognitive functioning in psychiatric disorders following deep brain stimulation. Brain Stimul. 2013;6(4):532–537.
   PubMed Web of Science ®Google Scholar
• Kohl S, Baldermann JC. Progress and challenges in deep brain stimulation for obsessive-compulsive disorder. Pharmacol Ther. 2018;186:168–175.
   PubMed Web of Science ®Google Scholar
• Karas PJ, Lee S, Jimenez-Shahed J, et al. Deep brain stimulation for obsessive compulsive disorder: evolution of surgical stimulation target parallels changing model of dysfunctional brain circuits. Front Neurosci. 2018;12:998.
   PubMed Web of Science ®Google Scholar
• Frost R, Steketee G, Amir N, et al. Cognitive assessment of obsessive-compulsive disorder. Behav Res Ther. 1997;35(4):281–291.
   PubMedGoogle Scholar
• Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the Ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg. 1996;84(2):203–214.
   PubMed Web of Science ®Google Scholar
• Hariz MI, Blomstedt P, Zrinzo L. Deep brain stimulation between 1947 and 1987: the untold story. FOC. 2010;29(2):E1–E10.
   Google Scholar
• Holtzheimer PE, Mayberg HS. Deep brain stimulation for psychiatric disorders. Annu Rev Neurosci. 2011;34:289–307.
   PubMed Web of Science ®Google Scholar
• Menchón JM, Real E, Alonso P, et al. A prospective international multi-center study on safety and efficacy of deep brain stimulation for resistant obsessive-compulsive disorder. Mol Psychiatry. 2019;26:1234–1247.
   PubMed Web of Science ®Google Scholar
• Little S, Pogosyan A, Kuhn AA, et al. Beta band stability over time correlates with parkinsonian rigidity and bradykinesia. Exp Neurol. 2012;236(2):383–388.
   PubMed Web of Science ®Google Scholar
• Pol S, Temel Y, Jahanshahi A. A custom made electrode construct and reliable implantation method that allows for long‐term bilateral deep brain stimulation in mice. Neuromodulation. 2020;24:212–219.
   PubMed Web of Science ®Google Scholar
• Liu L, Mariani SG, De Schlichting E, et al. Frameless ROSA® robot-assisted lead implantation for deep brain stimulation: technique and accuracy. Oper Neurosurg. 2020;19(1):57–64.
   Web of Science ®Google Scholar
• Paff M, Loh A, Sarica C, et al. Update on current technologies for deep brain stimulation in Parkinson's disease. J Mov Disord. 2020;13(3):185–198.
   PubMed Web of Science ®Google Scholar
• Kumar R, Singh A, Garg N. Acoustic cavitation-assisted formulation of solid lipid nanoparticles using different stabilizers. ACS Omega. 2019;4(8):13360–13370.
   PubMed Web of Science ®Google Scholar
• Giammalva GR, Gagliardo C, Marrone S, et al. Focused ultrasound in neuroscience. State of the art and future perspectives. Brain Sci. 2021;11(1):12–84.
   Web of Science ®Google Scholar
• Krishna V, Sammartino F, Rezai A. A review of the current therapies, challenges, and future directions of transcranial focused ultrasound technology advances in diagnosis and treatment. JAMA Neurol. 2018;75(2):246–254.
   PubMed Web of Science ®Google Scholar
• Fomenko A, Neudorfer C, Dallapiazza RF, et al. Low-intensity ultrasound neuromodulation: an overview of mechanisms and emerging human applications. Brain Stimul. 2018;11(6):1209–1217.
   PubMed Web of Science ®Google Scholar
• Hynynen K, Clement G. Clinical applications of focused ultrasound-the brain. Int J Hyperthermia. 2007;23(2):193–202.
   PubMed Web of Science ®Google Scholar
• Son S, Min HS, You DG, et al. Echogenic nanoparticles for ultrasound technologies: evolution from diagnostic imaging modality to multimodal theranostic agent. Nano Today. 2014;9(4):525–540.
   Web of Science ®Google Scholar
• Leinenga G, Langton C, Nisbet R, et al. Ultrasound treatment of neurological diseases-current and emerging applications. Nat Rev Neurol. 2016;12(3):161–174.
   PubMed Web of Science ®Google Scholar
• Lipsman N, Meng Y, Bethune AJ, et al. Blood–brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound. Nat Commun. 2018;9(1):1–8.
   PubMedGoogle Scholar
• Fishman MA, Antony A, Esposito M, et al. The evolution of neuromodulation in the treatment of chronic pain: Forward-looking perspectives. Pain Med. 2019;20(Supplement_1):S58–S68.,
   PubMedGoogle Scholar
• Lin PT, Ross EK, Chidester P, et al. Noninvasive neuromodulation in essential tremor demonstrates relief in a sham-controlled pilot trial. Mov Disord. 2018;33(7):1182–1183.
   PubMed Web of Science ®Google Scholar
• Patent US. Noise-free real time ultrasonic imaging of a treatment site undergoing high intensity focused ultrasound therapy; 2002.
   Google Scholar
• Mihran RT, Barnes FS, Wachtel H. Transient modification of nerve excitability in vitro by single ultrasound pulses. Biomed Sci Instr. 1990;26:235–246.
   PubMedGoogle Scholar
• Davidson B, Hamani C, Rabin JS, et al. Magnetic resonance-guided focused ultrasound capsulotomy for refractory obsessive compulsive disorder and major depressive disorder: clinical and imaging results from two phase I trials. Mol Psychiatry. 2020;25(9):1946–1957.
   PubMed Web of Science ®Google Scholar
• Schlesinger D, Benedict S, Diederich C, et al. MR-guided focused ultrasound surgery, present and future. Med Phys. 2013;40(8):080901.
   PubMed Web of Science ®Google Scholar
• Hynynen K, McDannold N, Vykhodtseva N, et al. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001;220(3):640–646.
   PubMed Web of Science ®Google Scholar
• Min BK, Bystritsky A, Jung KI, et al. Focused ultrasound-mediated suppression of chemically-induced acute epileptic EEG activity. BMC Neurosci. 2011;12(1):1–12.
   PubMedGoogle Scholar
• Legon W, Sato TF, Opitz A, et al. Transcranial focused ultrasound modulates the activity of primary somatosensory cortex in humans. Nat Neurosci. 2014;17(2):322–329.
   PubMed Web of Science ®Google Scholar
• Rezayat E, Toostani IG. A review on brain stimulation using low intensity focused ultrasound. Basic Clin Neurosci. 2016;7(3):187–194.
   PubMed Web of Science ®Google Scholar
• Fregni F, Freedman S, Pascual-Leone A. Recent advances in the treatment of chronic pain with non-invasive brain stimulation techniques. Lancet Neurol. 2007;6(2):188–191.
   PubMed Web of Science ®Google Scholar
• O'Neill BE, Karmonik C, Li KCP. An optimum method for pulsed high intensity focused ultrasound treatment of large volumes using the InSightec ExAblate® 2000 system. Phys Med Biol. 2010;55(21):6395–6410.
   PubMed Web of Science ®Google Scholar
• Liang S, Deng X, Ma P, et al. Recent advances in nanomaterial‐assisted combinational sonodynamic cancer therapy. Adv Mater. 2020;32:e2003214.
   PubMed Web of Science ®Google Scholar
• Ordeig O, Chin SY, Kim S, et al. An implantable compound-releasing capsule triggered on demand by ultrasound. Sci Rep. 2016;6(1):1–11.
   PubMedGoogle Scholar
• Cotero V, Miwa H, Graf J, et al. Peripheral focused ultrasound neuromodulation (pFUS). J Neurosci Methods. 2020;341:108721.
   PubMed Web of Science ®Google Scholar
• Su X, Thomas RG, Bharatula LD, et al. Remote targeted implantation of sound-sensitive biodegradable multi-cavity microparticles with focused ultrasound. Sci Rep. 2019;9(1):1–13.
   PubMedGoogle Scholar
• US20070060954A1. Method of using spinal cord stimulation to treat neurological disorders or conditions. Google Patents n.d. [cited 2020 Oct 13]. Available from: https://patents.google.com/patent/US20070060954A1/en
   Google Scholar
• US6016449A. System for treatment of neurological disorders. Google Patents n.d. [cited 2020 Oct 13]. Available from: https://patents.google.com/patent/US6016449A/en
   Google Scholar
• US6591138B1. Low frequency neurostimulator for the treatment of neurological disorders. Google Patents n.d. [cited 2020 Oct 13]. Available from: https://patents.google.com/patent/US6591138B1/en
   Google Scholar
• US6647296B2. Implantable apparatus for treating neurological disorders. Google Patents n.d. [cited 2020 Oct 13]. Available from: https://patents.google.com/patent/US6647296B2/en
   Google Scholar
• US7949403B2. Electrical stimulation device and method for the treatment of neurological disorders. Google Patents n.d. [cited 2020 Oct 13]. Available from: https://patents.google.com/patent/US7949403B2/en
   Google Scholar
• US20030028072A1. Low frequency magnetic neurostimulator for the treatment of neurological disorders. Google Patents n.d. [cited 2020 Oct 13]. Available from: https://patents.google.com/patent/US20030028072A1/en
   Google Scholar
• US20050154426A1. Method and system for providing therapy for neuropsychiatric and neurological disorders utilizing transcranical magnetic stimulation and pulsed electrical vagus nerve(s) stimulation. Google Patents n.d. [cited 2020 Oct 13]. Available from: https://patents.google.com/patent/US20050154426A1/en
   Google Scholar
• US20060129205A1. Method and system for cortical stimulation with rectangular and/or complex electrical pulses to provide therapy for stroke and other neurological disorders. Google Patents n.d. [cited 2020 Oct 13]. Available from: https://patents.google.com/patent/US20060129205A1/en
   Google Scholar
• Sharma A, Badea M, Tiwari S, et al. Wearable biosensors: an alternative and practical approach in healthcare and disease monitoring. Molecules. 2021;26(3):748.
   PubMed Web of Science ®Google Scholar
• Kourtis LC, Regele OB, Wright JM, et al. Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity. NPJ Digital Med. 2019;2(1):9.
   PubMedGoogle Scholar
• Frijia EM, Billing A, Lloyd-Fox S, et al. Functional imaging of the developing brain with wearable high-density diffuse optical tomography: a new benchmark for infant neuroimaging outside the scanner environment. Neuroimage. 2021;225:117490.
   PubMed Web of Science ®Google Scholar
• Pasluosta CF, Gassner H, Winkler J, et al. An emerging era in the management of Parkinson’s disease: wearable technologies and the internet of things. IEEE J Biomed Health Inform. 2015;19(6):1873–1881.
   PubMed Web of Science ®Google Scholar
• Saadeh W, Bin AMA, Butt SA. A wearable neuro-degenerative diseases detection system based on gait dynamics. IEEE/IFIP International Conference on VLSI and System-on-Chip, VLSI-SoC, IEEE Computer Society; 2017.
   Google Scholar
• Oung QW, Hariharan M, Lee HL, et al. Wearable multimodal sensors for evaluation of patients with Parkinson disease. Proceedings – 5th IEEE International Conference on Control System, Computing and Engineering, ICCSCE 2015, Institute of Electrical and Electronics Engineers Inc.; 2016. p. 269–74.
   Google Scholar
• Saied I, Chandran S, Arslan T. Integrated flexible hybrid silicone-textile dual-resonant sensors and switching circuit for wearable neurodegeneration monitoring systems. IEEE Trans Biomed Circuits Syst. 2019;13(6):1304–1312.
   PubMed Web of Science ®Google Scholar
• Madrid-Navarro CJ, Escamilla-Sevilla F, Mínguez-Castellanos A, et al. Multidimensional circadian monitoring by wearable biosensors in Parkinson's disease. Front Neurol. 2018;9:157.
   PubMed Web of Science ®Google Scholar
• Godoi BB, Amorim GD, Quiroga DG, et al. Parkinson's disease and wearable devices, new perspectives for a public health issue: an integrative literature review. Rev Assoc Med Bras. 2019;65(11):1413–1420.
   PubMed Web of Science ®Google Scholar
• Simonato M, Bennett J, Boulis NM, et al. Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013;9(5):277–291.
   PubMed Web of Science ®Google Scholar
• Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics. 2009;6(3):539–546.
   PubMed Web of Science ®Google Scholar
• Aryal M, Arvanitis CD, Alexander PM, et al. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv Drug Deliv Rev. 2014;72:94–109.
   PubMed Web of Science ®Google Scholar
• Tiwari A, Kumar R, Shefi O, et al. Fluorescent mantle carbon coated core-shell SPIONs for neuroengineering applications. ACS Appl Bio Mater. 2020;3(7):4665–4673.
   PubMedGoogle Scholar
• Kumar VB, Kumar R, Gedanken A, et al. Fluorescent metal-doped carbon dots for neuronal manipulations. Ultrason Sonochem. 2019;52:205–213.
   PubMed Web of Science ®Google Scholar
• Kumar VB, Kumar R, Friedman O, et al. One‐pot hydrothermal synthesis of elements (B, N, P)‐doped fluorescent carbon dots for cell labelling, differentiation and outgrowth of neuronal cells. ChemistrySelect. 2019;4(14):4222–4232.
   Web of Science ®Google Scholar
• Kumar R, Aadil KR, Ranjan S, et al. Advances in nanotechnology and nanomaterials based strategies for neural tissue engineering. J Drug Delivery Sci Technol. 2020;57:101617.
   Web of Science ®Google Scholar
• Kumar R, Kumar VB, Gedanken A. Sonochemical synthesis of carbon dots, mechanism, effect of parameters, and catalytic, energy, biomedical and tissue engineering applications. Ultrason Sonochem. 2020;64:105009.
   PubMed Web of Science ®Google Scholar
• Kang YJ, Cutler EG, Cho H. Therapeutic nanoplatforms and delivery strategies for neurological disorders. Nano Converg. 2018;5(1):35.
   PubMedGoogle Scholar
• Simrén J, Leuzy A, Karikari TK, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement. 2021;17:1145–1156.
   PubMed Web of Science ®Google Scholar
• Ueno M, Chiba Y, Murakami R, et al. Blood-brain barrier and blood-cerebrospinal fluid barrier in normal and pathological conditions. Brain Tumor Pathol. 2016;33(2):89–96.
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AAK, Dolman DEM, et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13–25.
   PubMed Web of Science ®Google Scholar
• Kaushik A, Jayant RD, Nair M. Advances in personalized nanotherapeutics. Springer International Publishing; 2017.
   Google Scholar
• Nair M, Jayant RD, Kaushik A, et al. Getting into the brain: potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev. 2016;103:202–217.
   PubMed Web of Science ®Google Scholar
• Kaushik A, Jayant RD, Bhardwaj V, et al. Personalized nanomedicine for CNS diseases. Drug Discov Today. 2018;23(5):1007–1015.
   PubMed Web of Science ®Google Scholar
• Sharma M, Dube T, Chibh S, et al. Nanotheranostics, a future remedy of neurological disorders. Expert Opin Drug Deliv. 2019;16(2):113–128.
   PubMed Web of Science ®Google Scholar
• Lockman PR, Mumper RJ, Khan MA, et al. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 2002;28(1):1–13.
   PubMed Web of Science ®Google Scholar
• Gao H, Shi W, Freund LB. Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci USA. 2005;102(27):9469–9474.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Anderson RGW, Brown MS. Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature. 1979;279(5715):679–685.
   PubMed Web of Science ®Google Scholar
• Lajoie JM, Shusta EV. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2015;55:613–631.
   PubMed Web of Science ®Google Scholar
• Salehi B, Calina D, Docea A, et al. Curcumin’s nanomedicine formulations for therapeutic application in neurological diseases. JCM. 2020;9(2):430.
   Google Scholar
• Tam VH, Sosa C, Liu R, et al. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier. Int J Pharm. 2016;515(1–2):331–342.
   PubMedGoogle Scholar
• Tosi G, Ruozi B, Belletti D. Nanomedicine: the future for advancing medicine and neuroscience. Nanomedicine. 2012;7(8):1113–1116.
   PubMed Web of Science ®Google Scholar
• Naz S, Beach J, Heckert B, et al. Cerium oxide nanoparticles: a “‘radical’ approach to neurodegenerative disease treatment”. Nanomedicine. 2017;12(5):545–553.
   PubMed Web of Science ®Google Scholar
• Mulik RS, Mönkkönen J, Juvonen RO, et al. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm. 2010;7(3):815–825.
   PubMedGoogle Scholar
• Roney CA, Arora V, Kulkarni PV, et al. Nanoparticulate radiolabelled quinolines detect amyloid plaques in mouse models of Alzheimer’s disease. Int J Alzheimers Dis. 2009;2009:1–8.
   Google Scholar
• Choudhury SD, Mohanty J, Pal H, et al. Cooperative metal ion binding to a cucurbit[7]uril-thioflavin T complex: demonstration of a stimulus-responsive fluorescent supramolecular capsule. J Am Chem Soc. 2010;132(4):1395–1401.
   PubMed Web of Science ®Google Scholar
• Martins PAT, Alsaiari S, Julfakyan K, et al. Self-assembled lipoprotein based gold nanoparticles for detection and photothermal disaggregation of β-amyloid aggregates. Chem Commun. 2017;53(13):2102–2105.
   PubMed Web of Science ®Google Scholar
• Hemmaragala NM, Arvidsson PI, Maguire GEM, et al. Interaction of beta-amyloid interactions with peptide functionalized gold nanoparticles. J Nanosci Nanotechnol. 2012;12(3):2179–2184.
   PubMed Web of Science ®Google Scholar
• Cui Z, Lockman PR, Atwood CS, et al. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur J Pharm Biopharm. 2005;59(2):263–272.
   PubMed Web of Science ®Google Scholar
• Hadavi D, Poot AA. Biomaterials for the treatment of Alzheimer's disease. Front Bioeng Biotechnol. 2016;4:49.
   PubMed Web of Science ®Google Scholar
• Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci. 2010;1184:154–172.
   PubMed Web of Science ®Google Scholar
• Schapira AHV. Treatment options in the modern management of Parkinson disease. Arch Neurol. 2007;64(8):1083–1088.
   PubMedGoogle Scholar
• Kulkarni AD, Vanjari YH, Sancheti KH, et al. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review. J Drug Target. 2015;23(9):775–788.
   PubMed Web of Science ®Google Scholar
• Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18(8):1061–1083.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Blakely EA, Bjornstad KA, et al. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm. 2007;328(1):86–94.
   PubMedGoogle Scholar
• McConathy WJ, Nair MP, Paranjape S, et al. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs. 2008;19(2):183–188.
   PubMed Web of Science ®Google Scholar
• Madhankumar AB, Slagle-Webb B, Mintz A, et al. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol Cancer Ther. 2006;5(12):3162–3169.
   PubMed Web of Science ®Google Scholar
• Ito A, Shinkai M, Honda H, et al. Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther. 2001;8(9):649–654.
   PubMed Web of Science ®Google Scholar
• Zhang S, Xiao M, Zhang Y, et al. Mimicking neuromelanin nanoparticles as a selective Pb2+ probe. Anal Chim Acta. 2020;1105:208–213.
   PubMed Web of Science ®Google Scholar
• Vashist A, Kaushik A, Vashist A, et al. Nanogels as potential drug nanocarriers for CNS drug delivery. Drug Discov Today. 2018;23(7):1436–1443.
   PubMed Web of Science ®Google Scholar
• Tomitaka A, Kaushik A, Kevadiya BD, et al. Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases. Drug Discov Today. 2019;24(3):873–882.
   PubMed Web of Science ®Google Scholar
• Kaushik A, Jayant RD, Nair M. Nanomedicine for neuroHIV/AIDS management. Nanomedicine. 2018;13(7):669–673.
   PubMed Web of Science ®Google Scholar
• Goldsmith M, Abramovitz L, Peer D. Precision nanomedicine in neurodegenerative diseases. ACS Nano. 2014;8(3):1958–1965.
   PubMed Web of Science ®Google Scholar
• Saraiva C, Praça C, Ferreira R, et al. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34–47.
   PubMed Web of Science ®Google Scholar
• Craparo EF, Bondì ML, Pitarresi G, et al. Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther. 2011;17(6):670–677.
   PubMed Web of Science ®Google Scholar
• Kaushik A, Jayant RD, Sagar V, et al. The potential of magneto-electric nanocarriers for drug delivery. Expert Opin Drug Deliv. 2014;11(10):1635–1646.
   PubMed Web of Science ®Google Scholar
• Jayant RD, Sosa D, Kaushik A, et al. Current status of non-viral gene therapy for CNS disorders. Expert Opin Drug Deliv. 2016;13(10):1433–1445.
   PubMed Web of Science ®Google Scholar
• Vashist A, Kaushik A, Vashist A, et al. Recent trends on hydrogel based drug delivery systems for infectious diseases. Biomater Sci. 2016;4(11):1535–1553.
   PubMed Web of Science ®Google Scholar
• Vashist A, Kaushik A, Alexis K, et al. Bioresponsive injectable hydrogels for on-demand drug release and tissue engineering. CPD. 2017;23(24):3595–3602.
   Google Scholar
• Vashist A, Kaushik A, Vashist A, et al. Advances in carbon nanotubes-hydrogel hybrids in nanomedicine for therapeutics. Adv Healthcare Mater. 2018;7(9):1701213.
   Web of Science ®Google Scholar
• Sun J, Roy S. Gene-based therapies for neurodegenerative diseases. Nat Neurosci. 2021;24(3):297–311.
   PubMed Web of Science ®Google Scholar
• Rabiei M, Kashanian S, Samavati SS, Jamasb S, et al. Active targeting towards and inside the brain based on nanoparticles: a review. Curr Pharm Biotechnol. 2020;21(5):374–383.
   PubMed Web of Science ®Google Scholar
• Kumar R, Butreddy A, Kommineni N, et al. Lignin: drug/gene delivery and tissue engineering applications. Int J Nanomedicine. 2021;16:2419–2441.
   PubMed Web of Science ®Google Scholar
• Cano A, Sánchez-López E, Ettcheto M, et al. Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. Nanomedicine. 2020;15(12):1239–1261.
   PubMed Web of Science ®Google Scholar
• Jaruszewski KM, Ramakrishnan S, Poduslo JF, et al. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer’s disease amyloid protein. Nanomedicine. 2012;8(2):250–260.
   PubMed Web of Science ®Google Scholar
• Gregori M, Masserini M, Mancini S. Nanomedicine for the treatment of Alzheimer's disease. Nanomedicine. 2015;10(7):1203–1218.
   PubMed Web of Science ®Google Scholar
• Hassanzadeh G, Fallahi Z, Khanmohammadi M, et al. Effect of magnetic tacrine-Loaded chitosan nanoparticles on spatial learning, memory, amyloid precursor protein and seladin-1 expression in the hippocampus of streptozotocin-exposed rats. Int Clin Neurosci J. 2016;3:25–31.
   Google Scholar
• Brenza TM, Schlichtmann BW, Bhargavan B, et al. Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery. J Biomed Mater Res A. 2018;106(11):2881–2890.
   PubMed Web of Science ®Google Scholar
• Tosi G, Ruozi B, Belletti D. Nanomedicine: the future for advancing medicine and neuroscience. Nanomedicine. 2012;7(8):1113–1116.
   PubMed Web of Science ®Google Scholar
• Kumar R, Kumar VB, Marcus M, et al. Element (B, N, P) doped carbon dots interaction with neural cells: promising results and future prospective. In: Parak WJ, Osiński M, editors. Colloidal nanoparticles for biomedical applications XIV, vol. 10892. SPIE; 2019. p. 22.
   Google Scholar
• Re F, Cambianica I, Zona C, et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine. 2011;7(5):551–559.
   PubMed Web of Science ®Google Scholar
• Goldsmith M, Abramovitz L, Peer D. Precision nanomedicine in neurodegenerative diseases. ACS Nano. 2014;8(3):1958–1965.
   PubMed Web of Science ®Google Scholar
• Kaushik A, Jayant RD, Nikkhah-Moshaie R, et al. Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers. Sci Rep. 2016;6(1):1–10.
   PubMedGoogle Scholar
• Kaushik A, Rodriguez J, Rothen D, et al. MRI-guided, noninvasive delivery of magneto-electric drug nanocarriers to the brain in a nonhuman primate. ACS Appl Bio Mater. 2019;2(11):4826–4836.
   PubMedGoogle Scholar
• Falconieri A, Vincentiis Raffa DS. Recent advances in the use of magnetic nanoparticles to promote neuroregeneration. Nanomedicine. 2019;14(9):1073–1076.
   PubMed Web of Science ®Google Scholar
• Kletetschka G, Bazala R, Takáč M, et al. Magnetic domains oscillation in the brain with neurodegenerative disease. Sci Rep. 2021;11(1):714.
   PubMed Web of Science ®Google Scholar
• Jayant R, Atluri V, Agudelo M, et al. Sustained-release nanoART formulation for the treatment of neuroAIDS. Int J Nanomedicine. 2015;10:1077–1093.
   PubMed Web of Science ®Google Scholar
• Jayant RD, Tiwari S, Atluri V, et al. Multifunctional nanotherapeutics for the treatment of neuroAIDS in drug abusers. Sci Rep. 2018;8(1):1–12.
   PubMedGoogle Scholar
• Kaushik A, Yndart A, Atluri V, et al. Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection. Sci Rep. 2019;9(1):1–11.
   PubMedGoogle Scholar
• Pandey P, Ghimire G, Garcia J, et al. Single-entity approach to investigate surface charge enhancement in magnetoelectric nanoparticles induced by AC magnetic field stimulation. ACS Sens. 2020;6:340–347.
   PubMed Web of Science ®Google Scholar
• Kaushik A, Nikkhah-Moshaie R, Sinha R, et al. Investigation of ac-magnetic field stimulated nanoelectroporation of magneto-electric nano-drug-carrier inside CNS cells. Sci Rep. 2017;7(1):1–12.
   PubMedGoogle Scholar
• Xu C, Qu X. Cerium oxide nanoparticle: a remarkably versatile rare earth nanomaterial for biological applications. NPG Asia Mater. 2014;6(3):e90–e90.
   Web of Science ®Google Scholar
• Cimini A, D'Angelo B, Das S, et al. Antibody-conjugated PEGylated cerium oxide nanoparticles for specific targeting of Aβ aggregates modulate neuronal survival pathways. Acta Biomater. 2012;8(6):2056–2067.
   PubMed Web of Science ®Google Scholar
• Nelson B, Johnson M, Walker M, et al. Antioxidant cerium oxide nanoparticles in biology and medicine. Antioxidants. 2016;5(2):15.
   Web of Science ®Google Scholar
• Zhang W, Hu S, Yin JJ, et al. Prussian blue nanoparticles as multienzyme mimetics and reactive oxygen species scavengers. J Am Chem Soc. 2016;138(18):5860–5865.
   PubMed Web of Science ®Google Scholar
• Brenza TM, Ghaisas S, Ramirez JEV, et al. Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy. Nanomedicine. 2017;13(3):809–820.
   PubMed Web of Science ®Google Scholar
• Zhang B, Yan W, Zhu Y, et al. Nanomaterials in neural-stem-cell-mediated regenerative medicine: imaging and treatment of neurological diseases. Adv Mater. 2018;30(17):1705694.
   PubMed Web of Science ®Google Scholar
• Marcus M, Baranes K, Park M, et al. Interactions of neurons with physical environments. Adv Healthcare Mater. 2017;6(15):1700267.
   Web of Science ®Google Scholar
• Mohajeri M, Behnam B, Barreto GE, et al. Carbon nanomaterials and amyloid-beta interactions: potentials for the detection and treatment of Alzheimer's disease? Pharmacol Res. 2019;143:186–203.
   PubMed Web of Science ®Google Scholar
• Fraczek-Szczypta A. Carbon nanomaterials for nerve tissue stimulation and regeneration. Mater Sci Eng C Mater Biol Appl. 2014;34:35–49.
   PubMed Web of Science ®Google Scholar
• Tran PA, Zhang L, Webster TJ. Carbon nanofibers and carbon nanotubes in regenerative medicine. Adv Drug Deliv Rev. 2009;61(12):1097–1114.
   PubMed Web of Science ®Google Scholar
• John AA, Subramanian AP, Vellayappan MV, et al. Carbon nanotubes and graphene as emerging candidates in neuroregeneration and neurodrug delivery. Int J Nanomedicine. 2015;10:4267–4277.
   PubMed Web of Science ®Google Scholar
• Mattson MP, Haddon RC, Rao AM. Molecular functionalization of carbon nanotubes and use as substrates for neuronal growth. J Mol Neurosci. 2000;14(3):175–182.
   PubMed Web of Science ®Google Scholar
• Jin G-Z, Kim M, Shin US, et al. Neurite outgrowth of dorsal root ganglia neurons is enhanced on aligned nanofibrous biopolymer scaffold with carbon nanotube coating. Neurosci Lett. 2011;501(1):10–14.
   PubMed Web of Science ®Google Scholar
• Keisham B, Seksenyan A, Denyer S, et al. Quantum capacitance based amplified graphene phononics for studying neurodegenerative diseases. ACS Appl Mater Interfaces. 2019;11(1):169–175.
   PubMed Web of Science ®Google Scholar
• Zhang DA, Rand E, Marsh M, et al. Carbon nanofiber electrode for neurochemical monitoring. Mol Neurobiol. 2013;48(2):380–385.
   PubMed Web of Science ®Google Scholar
• Chen W, Ouyang J, Yi X, et al. Black phosphorus nanosheets as a neuroprotective nanomedicine for neurodegenerative disorder therapy. Adv Mater. 2018;30.
   Web of Science ®Google Scholar
• Padmakumar S, Jones G, Pawar G, et al. Minimally invasive nasal depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain. J Control Release. 2021;331:176–186.
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release. 2003;87(1-3):187–198.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Lapierre J, Ojha CR, et al. Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation. Sci Rep. 2017;7(1):1–10.
   PubMedGoogle Scholar
• Kashyap K, Shukla R. Drug delivery and targeting to the brain through nasal route: mechanisms, applications and challenges. Curr Drug Deliv. 2019;16(10):887–901.
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7(23):1184–1189.
   PubMed Web of Science ®Google Scholar
• Vitorino C, Jorge A, Pais A. Recent trends in nanotechnology for brain delivery: a brief outlook. In: Nanoparticles for brain drug delivery. Jenny Stanford Publishing; 2020. p. 3–7.
   Google Scholar
• Machhi J, Shahjin F, Das S, et al. Nanocarrier vaccines for SARS-CoV-2. Adv Drug Deliv Rev. 2021;171:215–239.
   PubMed Web of Science ®Google Scholar
• Mittal D, Ali A, Md S, et al. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014;21(2):75–86.
   PubMed Web of Science ®Google Scholar
• Rabiee N, Ahmadi S, Afshari R, et al. Polymeric nanoparticles for nasal drug delivery to the brain: relevance to Alzheimer’s disease. Adv Therap. 2021;4(3):2000076.
   Google Scholar
• Jadhav K, Gambhire M, Shaikh I, et al. Nasal drug delivery system-factors affecting and applications. CDTH. 2007;2(1):27–38.
   Google Scholar
• Ugwoke MI, Agu RU, Verbeke N, et al. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005;57(11):1640–1665.
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379(1):146–157.
   PubMed Web of Science ®Google Scholar
• Bourganis V, Kammona O, Alexopoulos A, et al. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. 2018;128:337–362.
   PubMed Web of Science ®Google Scholar
• Xi J, Zhang Z, Si XA. Improving intranasal delivery of neurological nanomedicine to the olfactory region using magnetophoretic guidance of microsphere carriers. Int J Nanomed. 2015;10:1211–1222.
   PubMed Web of Science ®Google Scholar
• Ong W-Y, Shalini S-M, Costantino L. Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders n.d.
   Google Scholar
• Liu G, Men P, Harris PLR, et al. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett. 2006;406(3):189–193.
   PubMed Web of Science ®Google Scholar
• Nabi B, Rehman S, Fazil M, et al. Riluzole-loaded nanoparticles to alleviate the symptoms of neurological disorders by attenuating oxidative stress. Drug Dev Ind Pharm. 2020;46(3):471–483.
   PubMed Web of Science ®Google Scholar
• Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective–a review. Drug Deliv and Transl Res. 2013;3(1):42–62.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Saraf S, Saraf S, et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release. 2018;281:139–177.
   PubMed Web of Science ®Google Scholar
• Khan AR, Liu M, Khan MW, et al. Progress in brain targeting drug delivery system by nasal route. J Control Release. 2017;268:364–389.
   PubMed Web of Science ®Google Scholar
• Gonçalves J, Alves G, Carona A, et al. Pre-clinical assessment of the nose-to-brain delivery of zonisamide after intranasal administration. Pharm Res. 2020;37(4):1–16.
   Web of Science ®Google Scholar
• Cui W, Fu W, Lin Y, et al. Application of nanomaterials in neurodegenerative diseases. CSCR. 2021;16(1):83–94.
   Google Scholar
• Saeedi M, Eslamifar M, Khezri K, et al. Applications of nanotechnology in drug delivery to the central nervous system. Biomed Pharmacother. 2019;111:666–675.
   PubMed Web of Science ®Google Scholar
• Guo Q, Shen X, Tao Li Y, Yuan  , et al. Carbon nanotubes-based drug delivery to cancer and brain. J Huazhong Univ Sci Technol Med Sci. 2017;37(5):635–641.
   PubMedGoogle Scholar
• Kanwar J, Mahidhara G, Kanwar R. Recent advances in nanoneurology for drug delivery to the brain. CNANO. 2009;5(4):441–448.
   Google Scholar
• Pottoo FH, Javed MN, Rahman JU, et al. Targeted delivery of miRNA based therapeuticals in the clinical management of glioblastoma multiforme. Semin Cancer Biol. 2021;69:391–398.
   PubMed Web of Science ®Google Scholar
• Mahringer A, Puris E, Fricker G. Crossing the blood-brain barrier: a review on drug delivery strategies using colloidal carrier systems. Neurochem Int. 2021;147:105017.
   PubMed Web of Science ®Google Scholar
• Zinger A, Soriano S, Baudo G, et al. Biomimetic nanoparticles as a theranostic tool for traumatic brain injury. Adv Funct Mater. 2021;31(30):2100722.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sarkar B, Hsu CH, Wen ZH, et al. Future prospects of nanoparticles on brain targeted drug delivery. J Neurooncol. 2009;93(2):285–286.
   PubMed Web of Science ®Google Scholar
• Soni V, Pandey V, Asati S, et al. Design and fabrication of brain-targeted drug delivery. In: Basic fundamentals of drug delivery. Elsevier; 2018. p. 539–593.
   Google Scholar
• Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133–150.
   PubMed Web of Science ®Google Scholar
• Agrahari V, Burnouf P-A, Burnouf T, et al. Nanoformulation properties, characterization, and behavior in complex biological matrices: challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential. Adv Drug Deliv Rev. 2019;148:146–180.
   PubMed Web of Science ®Google Scholar
• Carroll RT, Bhatia D, Geldenhuys W, et al. Brain-targeted delivery of tempol-loaded nanoparticles for neurological disorders. J Drug Target. 2010;18(9):665–674.
   PubMed Web of Science ®Google Scholar
• Sun D, Zhuang X, Zhang S, et al. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv Drug Deliv Rev. 2013;65(3):342–347.
   PubMed Web of Science ®Google Scholar
• Gao N, Sun H, Dong K, et al. Gold-nanoparticle-based multifunctional amyloid-β inhibitor against Alzheimer’s disease. Chem Eur J. 2015;21:829–835.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Wu Q, Liang L, et al. Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson’s disease in the MPTP-induced mice model. J Drug Target. 2012;20(1):67–75.
   PubMed Web of Science ®Google Scholar
• Hasadsri L, Kreuter J, Hattori H, et al. Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem. 2009;284(11):6972–6981.
   PubMed Web of Science ®Google Scholar
• Tiwari MN, Agarwal S, Bhatnagar P, et al. Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism. Free Radic Biol Med. 2013;65:704–718.
   PubMed Web of Science ®Google Scholar
• Jafarieh O, Md S, Ali M, et al. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev Ind Pharm. 2015;41(10):1674–1681.
   PubMed Web of Science ®Google Scholar
• Gambaryan PY, Kondrasheva IG, Severin ES, et al. Increasing the efficiency of Parkinson’s disease treatment using a poly(lactic-co-glycolic acid) (PLGA) based L-DOPA delivery system. Exp Neurobiol. 2014;23(3):246–252.
   PubMedGoogle Scholar
• Zhang Y, Zhai M, Chen Z, et al. Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma. Drug Deliv. 2017;24(1):1045–1055.
   PubMed Web of Science ®Google Scholar
• Qin L, Wang CZ, Fan HJ, et al. A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy. Oncol Lett. 2014;8(5):2000–2006.
   PubMed Web of Science ®Google Scholar
• Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32(31):8010–8020.
   PubMed Web of Science ®Google Scholar
• Gao H, Qian J, Cao S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials. 2012;33(20):5115–5123.
   PubMed Web of Science ®Google Scholar
• Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative disorders. Maturitas. 2012;73(1):45–51.
   PubMed Web of Science ®Google Scholar
• Mahmoudi M, Laurent S, Shokrgozar MA, et al. Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell “vision” versus physicochemical properties of nanoparticles. ACS Nano. 2011;5(9):7263–7276.
   PubMed Web of Science ®Google Scholar
• Hutter E, Boridy S, Labrecque S, et al. Microglial response to gold nanoparticles. ACS Nano. 2010;4(5):2595–2606.
   PubMed Web of Science ®Google Scholar
• Tse JKY. Gut microbiota, nitric oxide, and microglia as prerequisites for neurodegenerative disorders. ACS Chem Neurosci. 2017;8(7):1438–1447.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhu G. Gut-brain axis and mood disorder. Front Psychiatry. 2018;9:223.
   PubMed Web of Science ®Google Scholar
• Raimondi MT, Albani D, Giordano C. An organ-on-a-chip engineered platform to study the microbiota–gut–brain axis in neurodegeneration. Trends Mol Med. 2019;25(9):737–740.
   PubMed Web of Science ®Google Scholar
• Westfall S, Lomis N, Kahouli I, et al. Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. Cell Mol Life Sci. 2017;74(20):3769–3787.
   PubMed Web of Science ®Google Scholar
• Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease-the gut-brain axis and environmental factors. Nat Rev Neurol. 2015;11(11):625–636.
   PubMed Web of Science ®Google Scholar
• Morais LH, Schreiber HL, Mazmanian SK. The gut microbiota–brain axis in behaviour and brain disorders. Nat Rev Microbiol. 2020;19:241–255.
   PubMed Web of Science ®Google Scholar